Business Context and Reporting Period
This Form 8-K Current Report was filed by Assembly Biosciences, Inc. (ASMB) on October 28, 2019. The filing discloses the appointment of Thomas J. Russo, CFA, as the Company's Chief Financial Officer and Principal Financial Officer, effective October 28, 2019. Mr. Russo replaces Michael P. Samar as Principal Accounting Officer, who will transition to the role of Senior Vice President, Finance and Business Operations.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics. This report focuses exclusively on executive compensation and appointment details.
Material Changes
The primary material change is the leadership transition in the finance department. Thomas J. Russo joins from Gilead Sciences Inc., where he served as Vice President, Head of Commercial Finance. The filing details the specific terms of his employment agreement, including base salary, bonus targets, sign-on bonuses, and equity grants.
Guidance, Outlook, and Compensation Details
The filing outlines the following compensation terms for the new CFO:
- Base Salary: $425,000 annually.
- Performance Bonus: Targeted at 40% of base salary.
- Sign-on Bonus: $100,000 payable within 30 days, subject to repayment if terminated under certain circumstances within 12 months.
- Equity Grant: Non-qualified stock option to purchase 185,000 shares. Vesting schedule: 25% on the first anniversary (October 28, 2020) and the remaining 75% in monthly installments over the subsequent 36 months.
- Severance Provisions:
- Change of Control: If terminated without cause or for good reason within 12 months of a change of control, benefits include 12 months of base salary, full target bonus, immediate equity vesting, and 12 months of COBRA reimbursement.
- Standard Termination: If terminated without cause or for good reason outside the change of control window, benefits include 12 months of base salary and 12 months of COBRA reimbursement.
Investor Verification Checklist
- Verify the full text of the Employment Agreement and Stock Option Agreement, which are referenced as exhibits to the Form 10-Q for the period ended September 30, 2019.
- Confirm the specific definitions of "cause," "good reason," and "change of control" within the executed agreements to understand severance triggers.
- Review the Company's upcoming 10-Q filing for the impact of the new equity grant on share count and dilution.
- Monitor the transition of duties between Mr. Russo and Mr. Samar to ensure continuity in financial reporting.